NEW YORK , Aug. 3, 2022 /PRNewswire/ -- As per Zion Market Research study, The global needle-free diabetes care market size was worth USD 9.1 billion in 2021 and is estimated to grow to USD 13.4 billion by 2028, with a compound annual growth rate (CAGR) of approximately 6.7% over the forecast period.
Needle-Free Diabetes Care Market: Overview
Diabetes is a collection of metabolic illnesses in which a person's blood sugar levels are elevated due to insufficient insulin production, improper cell response to insulin, or both or neither of these factors. To diagnose a patient, blood samples are typically drawn from them. This technique can result in needle-stick injuries, leading to several infections and suffering. People are using non-invasive, needle-free diabetic products as a result. During the projected period, an expanding patient population with diabetes and a rising prevalence of type 1 diabetes are expected to propel market expansion. Traditionally, patients with type 1 diabetes who need frequent glucose testing use needles, which raises the risk of infection and discomfort for people. The use of needle-free equipment reduces delivery discomfort and infection risk. Therefore, it is anticipated that there will be an increase in demand for these devices during the forecast period. Additionally, the industry has been driven by rising demand and technological developments in pain-free drug transportation and self-administration. However, the high cost of the facility and worries about technical difficulties are the factors anticipated to restrain the market's expansion for needle-free diabetes care.
Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): https://www.zionmarketresearch.com/sample/needle-free-diabetes-care-market
Our Free Sample Report Includes:
2022 Updated Report Introduction, Overview, and In-depth industry analysis
COVID-19 Pandemic Outbreak Impact Analysis Included
204 + Pages Research Report (Inclusion of Updated Research)
Provide Chapter-wise guidance on Request
2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
Includes an Updated List of tables & figures
Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis
Key Industry Insights & Findings of the Needle-Free Diabetes Care Market Reports:
As per the analysis shared by our research analyst, the Needle-Free Diabetes Care Market is expected to grow annually at a CAGR of around 6.7 % (2022-2028).
Through the primary research, it was established that the Needle-Free Diabetes Care Market was valued at approximately USD 9.1 billion in 2021 and is projected to reach roughly USD 13.4 billion by 2028.
One of the key factors propelling the expansion of the needle-free diabetes care market is the development of transdermal patches that measure blood sugar levels through the skin without extracting blood.
North America held a monopoly on the global needle-free diabetes care market in 2021. The significant market growth in North America is mainly due to the increased number of diabetics and the availability of technologically improved equipment.
The North America region dominance in the international arena has been aided by a high level of awareness regarding the potential advantages of needle-free drug delivery devices.
The market is expanding due to the availability of highly developed healthcare facilities and significant R&D spending by government agencies and pharmaceutical corporations to treat diabetes.
Zion Market Research published the latest report titled "Needle-Free Diabetes Care Market By Devices Types (Treatment Devices and Diagnostic Devices), By Treatment (Oral Insulin, Inhaled Insulin, Insulin Patch, and Others), By Application (Insulin Delivery and Other), By End-User (Diagnostic Centers, Hospitals & Clinics, and Others), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028." into their research database.
Needle-Free Diabetes Care Market: Growth Drivers
Increasing diabetes prevalence drives global needle-free diabetes care market growth.
Diabetes is anticipated to be the sixth most significant cause of death by 2030, according to the WHO. Stress, sedentary habits, poor diets, and obesity are the main diabetes risk factors. Physiological changes brought on by aging play a sizable role in diabetes risk. For instance, the International Diabetes Federation claims that the prevalence of diabetes rises with age. Therefore, those over 65 years old are thought to have the highest estimated risk of diabetes. Adults aged 20 to 24 had the lowest prevalence of diabetes (2.2% in 2021). Diabetes prevalence is at 24.0% among persons aged 75 to 79 as of 2021 and expected to rise to 24.7% by 2045. According to these figures, most diabetes will significantly grow over the next 25 years in nations with substantial geriatric populations. Therefore, it is anticipated that the need for needles less diabetes management solutions will be driven by the growing elderly population and the population's increased exposure to leading risk factors.
Needle-Free Diabetes Care Market: Restraints
More people using traditional diabetes management tools restraints the market demand.
Patients still favor conventional diabetes management strategies in various geographical areas. With their low cost and lack of information about linked devices and apps, many patients reject advanced platforms in favor of traditional blood glucose readers, glucose strips, insulin injections, prefilled syringes, and medication therapy. The limited knowledge for managing diabetes in various nations has also impacted the acceptance of cutting-edge technologies. The use of needle-less diabetes management has been negatively affected in Asia , the Middle East , and Africa due to low awareness, a lack of educated staff, and unfavorable/minimal reimbursements. The market expansion in China and India is also being constrained by the reliance on complementary traditional diabetes control techniques like herbal medications.
Directly Purchase a Copy of the Report @ https://www.zionmarketresearch.com/buynow/su/needle-free-diabetes-care-market
Global Needle-Free Diabetes Care Market: Segmentation
The global needle-free diabetes care market is segregated based on device types, treatment, application, end users, and region.
By treatment, the market is divided into oral insulin, inhaled insulin, insulin patch, and others. With its outstanding efficiency, the insulin patch segment was shown to have the fastest expanding market share in 2021. The significant growth rate can be ascribed to elements like the rising incidence of diabetes and growing public knowledge of sophisticated patch pumps. People with type 1 diabetes prefer insulin patch pumps since they do not need to carry an insulin infusion set. Patch pumps are chosen by older and working individuals because of their greater convenience. Patch pumps are generally smaller, more discrete, and easier to use than conventional insulin pumps. These pumps are also more affordable than traditional insulin delivery methods, which boosts demand. Patch pumps use an adhesive coating to bond to the skin and need minimal supervision. These pumps typically come with a blood glucose monitoring system or a continuous glucose monitor.
Based on application, the market is divided into insulin delivery and others. The global needle-free diabetes care market's most popular application area in 2021 was insulin delivery. The enormous population with diabetes drives the demand for insulin delivery devices. Additionally, the widespread use of recently introduced inventive pen devices and portable pumps is being aided by the rising demand for sophisticated insulin delivery systems, which is anticipated to accelerate market expansion.
Get More Insight before Buying@: https://www.zionmarketresearch.com/inquiry/needle-free-diabetes-care-market
List of Key Players in Needle-Free Diabetes Care Market:
Key questions answered in this report:
What are the growth rate forecast and market size for Needle-Free Diabetes Care Market?
What are the key driving factors propelling the Needle-Free Diabetes Care Market forward?
What are the most important companies in the Needle-Free Diabetes Care Market Industry?
What segments does the Needle-Free Diabetes Care Market cover?
How can I receive a free copy of the Needle-Free Diabetes Care Market sample report and company profiles?
By Product Type, By Application, And By End Use
Value (USD Billion), and Volume (Units)
Revenue in USD million/billion and CAGR from 2022 to 2028
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
European Pharma Group, Medical International Technology Inc., Antares Pharma Inc., Zogenix Inc., 3M Company, Valeritas Inc., Endo International plc., INJEX Pharma AG, and Bioject Medical Technologies Inc.
Market growth drivers, restraints, opportunities, Porter's five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Avail of customized purchase options to meet your exact research needs.
https://www.zionmarketresearch.com/custom/6016
Free Brochure: https://www.zionmarketresearch.com/requestbrochure/needle-free-diabetes-care-market
In May 2022 , Endo International plc announced that its subsidiary Endo Ventures Limited (EVL) had acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc.
Growing prevalence of diabetics likely to help North America dominate the global market.
North America held a monopoly on the global needle-free diabetes care market in 2021. The significant market growth in North America is mainly due to the increased number of diabetics and the availability of technologically improved equipment. By 2025, there are likely to be 5 million Canadians living with diabetes, according to the Canadian Diabetes Association. Therefore, it is anticipated that the vast patient population suffering from diabetes and its rising prevalence will spur growth in this area. The region's dominance in the international arena has been aided by a high level of awareness regarding the potential advantages of needle-free drug delivery devices. Additionally, the market is expanding due to the availability of highly developed healthcare facilities and significant R&D spending by government agencies and pharmaceutical corporations to treat diabetes.
Global Needle-Free Diabetes Care Market is segmented as follows:
Needle-Free Diabetes Care Market: By Devices Types Outlook (2022-2028)
Needle-Free Diabetes Care Market: By Treatment Outlook (2022-2028)
Needle-Free Diabetes Care Market: By Application Outlook (2022-2028)
Needle-Free Diabetes Care Market: By End User Outlook (2022-2028)
Hospitals & Clinics And Other
Needle-Free Diabetes Care Market: By Region Outlook (2022-2028)
Rest of Middle East & Africa
Press Release For Needle-Free Diabetes Care Market: https://www.zionmarketresearch.com/news/global-needle-free-diabetes-care-market
Browse Other Related Research Reports from Zion Market Research
DHA from Algae Market - Global Industry Analysis: The global DHA from algae market size was worth around USD 384.1 million in 2021 and is estimated to grow to about USD 569.9 million by 2028, with a compound annual growth rate (CAGR) of approximately 6.8% over the forecast period.
Endocrine Peptide Test Market - Global Industry Analysis: The global endocrine peptide test market was worth around $7.04 billion in 2021 and is predicted to grow to around $11 billion by 2028 at a CAGR rate of 8% over the forecast period.
Hospital-Acquired Infection Control Market - Global Industry Analysis: The global hospital-acquired infection control market was valued at USD 28.99 billion in 2021. The global market is projected to grow to about USD 34.03 billion at a CAGR of 9.89% by 2028.
Browse through Zion Market Research's coverage of the Global Healthcare Industry
Follow Us on: LinkedIn | Twitter | Facebook
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, and company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research 244 Fifth Avenue, Suite N202 New York , 10001, United States Tel: +49-322 210 92714 USA /Canada Toll-Free No.1-855-465-4651 Email: sales@zionmarketresearch.com Website: https://www.zionmarketresearch.com/
Logo: https://mma.prnewswire.com/media/1605489/Zion_Market_Research_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/13-4-billion-global-needle-free-diabetes-care-market-size-likely-to-grow-at-6-7-cagr-during-2022-2028--industry-trends-share-growth-swot-analysis-forecast-by-zion-market-research-301599080.html
New drugs from Eli Lilly and Novo Nordisk have shown striking results in studies. If insurers step up to back them, the drugs—and the stocks—could take off.
UNITY Biotechnology Inc (NASDAQ: UBX) shares are skyrocketing after 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325 for diabetic macular edema (DME). DME is a diabetic complication that affects the blood vessels in the back of your eye. At 18 weeks after a single UBX1325 injection, the mean change in BCVA of UBX1325-treated subjects was an increase of 6.1 ETDRS letters, representing an improvement of +5.0 ETDRS letters compared to sham-treated subjects. Related: UNITY Biotech Stock
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
Alibaba Group Holding Limited (NYSE: BABA) and Tencent Holding Ltd (OTC: TCEHY) submitted the algorithm details of some of their products to China's top internet watchdog, Reuters reports. The submission was a part of China's sweeping crackdown on the sector. The internet platforms faced flak for abusing algorithms to invade user privacy and manipulate their choices. The Cyberspace Administration of China (CAC) published a list of 30 algorithms used in some of the country's most popular apps, in
In this article, we discuss 10 cheap oil stocks to buy today. If you want to skip our detailed analysis of these stocks, go directly to 5 Cheap Oil Stocks to Buy Today. With WTI crude oil prices topping $120 per barrel as recently as mid-June, concerns over rising interest rates and a potential U.S. […]
Kazakhstan is expected to sell some of its crude oil through Azerbaijan's biggest oil pipeline from September, as the nation seeks alternatives to a route Russia threatened to shut, three sources familiar with the matter said. For 20 years, they have been shipped through the CPC pipeline to Russia's Black Sea port of Novorossiisk, which provides access to the global market. In July a Russian court threatened to shut the CPC, prompting the Kazakh government and major foreign producers to set up contracts for other outlets as a precaution.
The U.S. Centers For Disease Control and Prevention has relaxed some guidelines around COVID-19, including the quarantine recommendation for people who have been exposed. Officials say the new guidelines are meant to educate people on how to stay safe without causing much disruption to life, school and work.
The pharma giant hit back at allegations that the use of Zantac, known chemically as ranitidine, increases the risk of cancer.
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
(TSX: CWEB) (OTC: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web," "CW" or the "Company"), the market leader in full-spectrum hemp extract CBD products, today announced plans to unveil a product line catering to the sports vertical. The products are currently undergoing the NSF for Sport® certification process with NSF, a third-party organization that manufacturers, regulators, and consumers look to for the development of public health standards and certification marks that help protect
Analysts at Goldman Sachs said commodity markets were behaving irrationally, and warned of "unsustainable prices." Prices and inventories are falling, while demand is beating expectations and supply is disappointing, they said in a note late Thursday. Normally, a combination of higher demand and lower supply would make prices rise. The bank lowered its forecast for Brent prices earlier this week. It now predicts $125 a barrel in three months' time and $120 a barrel in 12 months. Goldman Sachs pr
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
The study, which was recently published in the journal “Scientific Reports,” found that gait patterns among Japanese children aged 6 to 12 vary from those in other developed countries. Age related variations in lower limb movements while walking were studied by scientists from Nagoya University in Japan. For Japanese children in the 11-12 year age group, the number of steps performed each minute was higher than those in the 6-8 year age group.
U.S. manufacturing would make certain vehicle models eligible for a tax credit under the Inflation Reduction Act, a $430 billion bill focused on lowering healthcare costs, promoting clean energy and increasing corporate taxes. Demand for electric vehicles has surged as countries worldwide chase cleaner transport options and seek to achieve net-zero carbon emissions targets to tackle climate change. Production of the Ocean sports utility vehicle (SUV) is slated to begin this November at contract manufacturer Magna International's Austrian unit.
Let's check out a few charts of crude oil prices to see if the rally is resuming. In this daily bar chart of the nearby crude oil futures contract, below, we can see that prices are trying to regain their strength and close back above the rising 200-day moving average line. The daily On-Balance-Volume (OBV) looks like it has been improving in August.
(Bloomberg) -- Mexico — which imports nearly all of the natural gas it burns — has laid out a somewhat surprising mission: to become one of the world’s top exporters of the fuel, and fast.Most Read from BloombergAuthor Salman Rushdie Attacked on Lecture Stage in New YorkThe Fed’s Damage to the Housing Market May Last YearsStriking Drop in Stress Hormone Predicts Long Covid in StudyTrump Calls for Release of Warrant Documents Used in SearchPutin’s War Sends Russian Economy Back to 2018 in Single
Demand remains strong for automakers, with supply constraints preventing inventory buildup and supporting strong pricing.
The administration said in March it would release a record 1 million barrels of crude per day from May to October, or about 180 million barrels, from the SPR, which holds oil in caverns on the coasts of Louisiana and Texas. The companies buying oil included Valero Energy Corp, with 4.9 million barrels, Motiva Enterprises LLC, with 2.1 million barrels, Phillips 66 with 950,000 barrels and Chevron Corp with 350,000 barrels.
Karuna Therapeutics (KRTX) is progressing well with its pipeline development. KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.